GERN - ジェロン (Geron Corporation) ジェロン



symbol GERN
会社名 Geron Corp. (ジェロン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジェロン(Geron Corporation)はJanssen Biotech Inc. (Janssen)による血液骨髄性悪性腫瘍でファーストインクラスのテロメラーゼ阻害剤、imetelstatを開発する臨床段階のバイオ医薬品会社である。同社は、腫瘍学治療薬の開発に従事している。テロメラーゼのリボ核酸(RNA)鋳型に高親和性で結合し、それによってテロメラーゼ活性を直接阻害するオリゴヌクレオチドであるように、その核酸化学を用いて、イメテスタットを設計した。JanssenはIMbarkと呼ばれる骨髄線維症(MF)の第II相試験、IMergeと呼ばれる骨髄異形成症候群(MDS)の第II / III相試験などの2つの臨床試験でImetelstatの開発に従事する。Imetelstatは、テロメラーゼのRNA鋳型に相補的であり、それと高親和性で結合するように設計され、それによってテロメラーゼ活性を直接阻害するように設計された脂質結合13merオリゴヌクレオチドである。   ジェロンは米国のバイオ医薬品会社で、抗がん剤の開発に焦点に置く。現在製品化に向け、リンパ増殖性疾患、多発性骨髄腫、非小細胞肺がん、乳がん、急性骨髄性白血病のテロメラ―ゼ阻害剤であるイメテルスタットの治験を行う。また、骨髄線維症に対するテロメラ―ゼ阻害剤の予備研究を行う。   Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
本社所在地 149 Commonwealth Drive Suite 2070 Menlo Park CA 94025 USA
代表者氏名 Hoyoung Huh 湖寧
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-473-7700
設立年月日 33178
市場名 NASDAQ National Market System
ipoyear 1996年
従業員数 42人
EBITDA EBITDA(百万ドル) -29.64000
終値(lastsale) 1.835
時価総額(marketcap) 336946417.71
時価総額 時価総額(百万ドル) 306.64880
売上高 売上高(百万ドル) 0.88000
企業価値(EV) 企業価値(EV)(百万ドル) 145.72180
当期純利益 当期純利益(百万ドル) -28.44800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Geron Corporation revenues decreased 26% to $526K. Net loss increased 4% to $14.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 23% to $6.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.09 to -$0.08.



   Geron Conducts End of Phase 2 Meeting for Imetelstat in Relapsed/Refractory Myelofibrosis  2019/12/18 21:30:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that the Company has conducted an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of the IMbark Phase 2 clinical trial of imetelstat in patients with Intermediate-2 or High-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment, or relapsed/refractory MF. Based on feedback from the meeting, over the comi
   Geron Reports Two Poster Presentations at American Society of Hematology Annual Meeting  2019/12/10 14:15:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that two posters related to imetelstat, the Company’s first-in-class telomerase inhibitor, were presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida on December 8 and 9. Both posters are available on Geron’s website at Trials in Progress Poster Presentation Title: IMerge: A Study to Evaluate Imetelstat (GRN163L) in Transfus
   Geron Announces Appointment of New Executive to Focus on Corporate Strategy  2019/12/03 13:00:00 Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate Strategy and Chief Commercial Officer. With this appointment, all functions of a fully-integrated, late-stage drug development executive leadership team are now in place. “We are pleased to welcome Anil whose proven track record in shaping hematology-oncology development programs, launching blockbuster oncology products and managing external
   Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?  2019/11/29 08:24:00 Zacks Investment Research
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
   Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%  2019/11/07 07:50:00 Zacks Investment Research
Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.
   Geron Corporation (GERN) CEO John Scarlett on Q1 2019 Results - Earnings Call Transcript  2019-05-16
Geron Corporation. (GERN) Q1 2019 Results Earnings Conference Call May 16, 2019, 09:00 AM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Andrew Grethlein - Chief Operating Officer Aleksandra…
   Geron down 6% on extended timeline for imetelstat in myelofibrosis  2019-05-16
Geron ( GERN -5.9% ) slips on below-average volume in apparent response to its revised development timeline for imetelstat in myelofibrosis. More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Read more …
   Geron: A Very Long Wait For A Very Long Shot  2019-05-03
After Geron's ( GERN ) stock price experienced a meteoric rise and equally spectacular fall in the second half of 2018, it appears as though the stock might finally be about to stabilize. After reaching an intra-day high of $6.99 (market cap of $1.29B) on 09/13/18, Johnson & Johnson-owned …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジェロン GERN Geron Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)